Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

NCT02400476 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.

NCT NCT02400476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02400476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Lead sponsor
Puma Biotechnology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
April 22, 2021
Enrollment
563 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

early stage her2+ breast cancer